Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin

Journal of the Royal College of Physicians of Edinburgh

Volumn 40, Issue 1, 2010, Pages 33-36

  Teckchandani, S ^a   Robertson, S ^a   Almond, A ^a   Donaldson, K ^a   Isles, C ^a  

^a DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antimicrobial; Drug interaction; Fusidic acid; Rhabdomyolysis; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ATENOLOL; ATORVASTATIN; BILIRUBIN; CREATINE KINASE; CREATININE; CYTOCHROME P450 3A; DICLOFENAC; EZETIMIBE; FLUCLOXACILLIN; FUSIDIC ACID; GAMMA GLUTAMYLTRANSFERASE; ISOENZYME; RAMIPRIL; SIMVASTATIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CREATININE BLOOD LEVEL; DIALYSIS; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME ACTIVITY; HEART INFARCTION; HIP PROSTHESIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION; KIDNEY INJURY; LIVER FUNCTION TEST; MALE; MULTIPLE ORGAN FAILURE; MUSCLE STRENGTH; MUSCLE WEAKNESS; PRESCRIPTION; RHABDOMYOLYSIS;

AGED; ANTICHOLESTEREMIC AGENTS; DRUG INTERACTIONS; FUSIDIC ACID; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRROLES; RHABDOMYOLYSIS;

EID: 77949531109     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2010.108     Document Type: Article

References (53)

1. Bellosta S, Paoletti R, Corsini A. Safety of statins. Focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109:50-7. doi:10.1161/01.CIR.0000131519.15067.1f
2. Pasternak RC, Smith SC, Bairey-Merz CN et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40:567-72. doi:10.1016/S0735-1097(02)02030-2
3. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116:408-16. doi:10.1016/j.amjmed.2003.10.033
4. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007; 49:1753-62. doi:10.1016/j.jacc.2007.01.067
5. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370:1781-90. doi:10.1016/S0140-6736(07)60716-8
6. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18:401-8. doi:10.1097/MOL.0b013e32825a6773
7. Radcliffe KA, Campbell WW. Statin myopathy. Curr Neurol Neurosci Rep 2008; 8:66-72. doi:10.1007/s11910-008-0011-4
8. Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008; 337:a2286. doi:10.1136/bmj.a2286
9. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97:52C-60C. doi:10.1016/j.amjcard.2005.12.010
10. Molden E, Skovlund E, Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Saf 2008; 31:587-96. doi:10.2165/00002018-200831070-00004
11. Joint Formulary Committee. British National Formulary. 58th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009.
12. Sodium fusidate: summary of product characteristics. Available from: http://emc.medicines.org.uk
13. Wenisch C, Krause R, Fladerer P et al. Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. Am J Med 2000; 109:78. doi:10.1016/S0002-9343(00)00367-3
14. Kahri J, Valkonen M, Backlund T et al. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur J Clin Pharmacol 2005; 60:905-7. doi:10.1007/s00228-004-0858-5
15. Nwaejike N, Sidhu P. A note to cardiothoracic surgeons: statins can interact with ciprofloxacillin and fusidic acid to cause rhabdomyolysis and myoglobinuric renal failure. Internet J Thorac Cardiovasc Surg 2007: 8(2): letters to the editor.
16. O'Mahony C, Campbell VL, Al-Khayatt MS et al. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J 2008; 84:325-7. doi:10.1136/pgmj.2007.064097
17. Kotanko P, Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus and fusidic acid. Nephron 2002; 90:234-5. doi:10.1159/000049053
18. Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust 2003; 179:172.
19. Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia 2008; 63:656-8. doi:10.1111/j.1365-2044. 2007.05434.x
20. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when co-administered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94:1140-6. doi:10.1016/j.amjcard. 2004.07.080
21. Jacobsen W, Kirchner G, Hallensleben K et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999; 27:173-9.
22. Kantola T, Backman JT, Niemi M et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000; 56:225-9. doi:10.1007/s002280000127
23. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001; 40:263-81. doi:10.2165/00003088-200140040-00003
24. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35:26-31. doi:10.1345/aph.10177
25. Kahri AJ, Valkonen MM, Vuoristo MK et al. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. Ann Pharmacother 2004; 38:719. doi:10.1345/aph.1D243
26. Valero R, Rodrigo E, Zubimendi JA et al. [Rhabdomyolysis secondary to the interaction of statins with macrolides in a renal transplant patient.] Nefrologia 2004; 24:382-3. In Spanish.
27. Trieu J, Emmett L, Perera C et al. Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy. Clin Nucl Med 2004; 29:803-4. doi:10.1097/00003072- 200412000-00008
28. Chouhan UM, Chakrabarti S, Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother 2005; 39:1760-1. doi:10.1345/aph.1G195
29. Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy 2007; 27:603-7. doi:10.1592/phco.27.4.603
30. Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64:177-82. doi:10.1016/S0009-9236(98)90151-5
31. Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999; 22:295-7.
32. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38:111-80. doi:10.2165/00003088-200038020-00002
33. Itakura H, Vaughn D, Haller DG et al. Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. J Urol 2003; 169:613. doi:10.1016/S0022-5347(05)63967-5
34. Akram K, Rao S, Parker M. A lesson for everyone in drug-drug interactions. Int J Cardiol 2007; 118:e19-20. doi:10.1016/j.ijcard.2006. 11.235
35. Hazin R, Abuzetun JY, Suker M et al. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc 2008; 100:444-6.
36. Moro H, Tsukada H, Tanuma A et al. Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. AIDS Patient Care STDS 2004; 18:687-93. doi:10.1089/apc.2004.18.687
37. Shaukat A, Benekli M, Vladutiu GD et al. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003; 37:1032-5. doi:10.1345/aph.1C467
38. Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS 2003; 17:207-10. doi:10.1089/108729103321655854
39. Sipe BE, Jones RJ, Bokhart GH. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole and clarithromycin interaction. Ann Pharmacother 2003; 37:808-11. doi:10.1345/aph.1C396
40. Siedlik PH, Olson SC, Yang BB, Stern RH. Erythromycin co-administration increases plasma atorvastatin concentrations. J Clin Pharmacol 1999; 39:501-4.
41. Lipitor: summary of product characteristics. Available from: http://emc.medicines.org.uk
42. Cooper KJ, Martin PD, Dane AL et al. The effects of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003; 59:51-6.
43. Cooper KJ, Martin PD, Dane AL et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002; 58:527-31. doi:10.1007/s00228-002-0508-8
44. McTaggart F, Buckett L, Davidson R et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87:28B-32B. doi:10.1016/S0002- 9149(01)01454-0
45. Baxter K, Marshall A, Sharp J. Drug interactions that can occur with statins and macrolide antibacterials. Pharm J 2008; 280:630.
46. Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64:58-65. doi:10.1016/S0009-9236(98)90023-6
47. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63:332-41. doi:10.1016/S0009-9236(98)90165-5
48. Simes J, Furberg CD, Braunwald E et al. for the Prospective Pravastatin Pooling Project Investigators. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels: the Prospective Pravastatin Pooling Project. Eur Heart J 2002; 23:207-15. doi:10.1053/euhj.2001.2775
49. Schindler C, Thoms M, Matschke K et al. Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin. Clin Ther 2007; 29:172-6. doi:10.1016/j.clinthera.2007.01.017
50. Saito M, Hirata-Koizumi M, Urano T et al. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther 2005; 30:21-37. doi:10.1111/j.1365-2710.2004.00605.x
51. Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Op Drug Saf 2004; 3:547-57. doi:10.1517/14740338.3.6.547
52. Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized control trials. Am J Cardiol 2008; 102:1654-62. doi:10.1016/j.amjcard. 2008.08.014
53. Stang P, Morris L, Kempf J et al. The coprescription of contra-indicated drugs with statins: continuing potential for increased risk of adverse events. Am J Ther 2007; 14:30-40. doi:10.1097/01.mjt.0000208875.61480.c8